Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 3Melanoma 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Moderate Hepatic Impairment 1Meningioma 1Lymphoma 1Lung Neoplasms 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Hematologic Neoplasms 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

lutetium Lu 177 dotatate 2Magnetic Resonance Spectroscopy 2olaparib 1gallium Ga 68 dotatate 1capivasertib 1abemaciclib 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1Lysine 1Hydroxyurea 1HhAntag691 1Ga(III)-DOTATOC 1GSK2256098 1Everolimus 1Bevacizumab 1Arginine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × capivasertib × 30 days × Clear all
NCT02523014 2026-06-02

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
124 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡